Our April 2020 cardiac safety white paper, “The changing landscape of cardiac safety’ is now available to download here. This white paper summarises current cardiac safety testing guidelines and Metrion Biosciences’ involvement in creating an enhanced panel of assays aligned with future cardiac safety testing and drug regulatory requirements.
Please contact us if you would like any further information regarding our suite of cardiac safety services.
Our exclusive white paper, “Improving biological tools for disease modelling and drug discovery: Human iPSC-derived Atrial Cardiomyocytes” is available to download here. This collaboration with Axol Bioscience enabled us to validate human iPSC-derived atrial cardiomyocytes as a model system for improving atrial fibrillation drug discovery and disease modelling.
Please also contact us if you would like any further information regarding our iPSC derived cardiomyocyte characterisation services.